OpACIN-neo and PRADO
OpACIN-neo and PRADO: Effect of Response-Directed Treatment Personalization on Survival After Neoadjuvant Immune Checkpoint Blockade in Stage III Melanoma

Released: June 09, 2023

Activity

Progress
1
Course Completed